MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate & Evaluate Its Mo...

MabCure Inc., (OTCBB:MBCI) a leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

These antibodies were developed earlier by MBCI and have shown significant promise in detecting ovarian cancer in blood samples and distinguishing between cancer and benign tumors of the ovaries. The results were presented last year at the annual meeting of the Society of Gynecological Oncologists (SGO) http://www.mabcure.com/MBCI-SGO.pdf

In order to further develop these antibodies as diagnostic reagents, they will be the subject of further evaluation and characterization at CUNY CAT. The work will be carried out in the laboratory of Professor Paul Gottlieb at the City College of New York’s Sophie Davis School of Biomedical Education. This contractual agreement will permit the MBCI antibodies to be tested and validated in an independent setting.

Following validation, the Company plans to evaluate the performance of its antibodies in diagnosing ovarian cancer in blood samples obtained from its completed Thai study as well as samples obtained from patients previously admitted to the Department of Gynecologic Oncology, Catholic University Hospital, Leuven, Belgium.

Dr. Amnon Gonenne, CEO, stated, “MabCure looks forward to accomplishing its goals of developing a definitive test for the early detection of ovarian cancer, validating and expanding its earlier results. The interaction with CUNY CAT organization gives us the advantage not only of access to their scientific expertise, but also to participate in the larger mission of the CAT as it seeks to support early stage biotechnology initiatives in the area”.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which we plan to develop as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure’s initial goal is to develop its novel MAbs as diagnostic tools for the detection of ovarian and prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website at www.mabcure.com.

This news release contains “forward-looking statements”. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.